MCI patients declining and not-declining at Mid-Term follow-up: FDG-PET findings

Current Alzheimer Research

Volumn 7, Issue 4, 2010, Pages 287-294

  Pagani, M ^a,d   Dessi, B ^b   Morbelli, S ^c   Brugnolo, A ^b   Salmaso, D ^a   Piccini, A ^b   Mazzei, D ^b   Villavecchia, G ^e   Larsson, S A ^d   Rodriguez, G ^b   Nobili, F ^b  

^a INSTITUTE OF COGNITIVE SCIENCES AND TECHNOLOGIES   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e GALLIERA HOSPITAL   (Italy)

Author keywords

Alzheimer's disease; Amnestic mild cognitive impairment; Episodic memory; Fdg pet

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; BRAIN MAPPING; BRAIN METABOLISM; BRAIN REGION; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; EPISODIC MEMORY; FEMALE; FOLLOW UP; FUSIFORM GYRUS; HIPPOCAMPUS; HUMAN; LEFT HEMISPHERE; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; PRIORITY JOURNAL; SUBICULUM; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; BRAIN MAPPING; COGNITION DISORDERS; DEMENTIA; DISEASE PROGRESSION; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; FUNCTIONAL LATERALITY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MEMORY DISORDERS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 77953963850     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510791162368     Document Type: Article

References (49)

1. Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6: 734-746 (2007).
2. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 30: 1104-1113 (2003).
3. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, et al. MCI conversion to dementia and the APOE genotype. A prediction study with FDG-PET. Neurology 63: 2332-2340 (2004).
4. Anchisi D, Borroni B, Franceschi F, Kerrouche N, Kalbe E, Beuthien-Beumann B, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 62: 1728-1733 (2005).
5. Mosconi L, Tsui WH, Pupi A, De Santi S, Drzezga A, Minoshima S, et al. 18F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease. J Nucl Med 48: 1129-1134 (2007).
6. Hunt A, Schönknecht P, Henze M, Seidl U, Haberkorn U, Schröder J. Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease. Psychiatry Res: Neuroimaging 155: 147-154 (2007).
7. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 49: 390-398 (2008).
8. Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and 18F-FDG PET. J Nucl Med 46: 1625-1632 (2005).
9. Nobili F, Salmaso D, Morbelli S, Girtler N, Piccardo A, Brugnolo A, et al. Principal component analysis of FDG PET in amnestic MCI. Eur J Nuc Med Mol Imaging 35: 2191-2202 (2008).
10. Masur DM, Sliwinski M, Lipton RB, Blau AD, Crystal HA. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology 44: 1427-1432 (1994).
11. Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment. A population-based validation study. Neurology 56: 37-42 (2001).
12. Jagust W. Is amnestic mild cognitive impairment always AD? Neurology 70: 502-503 (2008).
13. Mori E, Hirono N, Yamashita H, Imamura T, Ikejiri Y, Ikeda M, et al. Premorbid brain size as a determinant of reserve capacity against intellectual decline in Alzheimer's disease. Am J Psychiatry 154: 18-24 (1997).
14. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198 (1975).
15. Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index of ADL. Gerontologist 10: 20-30 (1970).
16. Lawton MP, Brody EM. Assessment of older people; selfmantaining and instrumental activities of daily living. Gerontologist 9: 179-186 (1969).
17. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314 (1994).
18. Loeb C, Gandolfo C. Diagnostic evaluation of degenerative and vascular dementia. Stroke 14: 399-401 (1983).
19. Masur DM, Fuld PA, Blau AD, Thal LJ, Levin HS, Aronson MK. Distinguishing normal and demented elderly with selective reminding test. J Clin Exp Neuropsychol 11: 615-630 (1989).
20. Carlesimo GA, Caltagirone C, Gainotti G. The mental deterioration battery: normative data, diagnostic reliability and qualitative analysis of cognitive impairment. The group for the standardization of the mental deterioration battery. Eur Neurol 36: 378-384 (1996).
21. Spinnler H, Tognoni G. Standardizzazione e taratura Italiana di test neuropsicologici. Ital J Neurol Sci 6(Suppl 8): 1-120 (1987).
22. Barbarotto R, Laiacona M, Frosio R, Vecchio M, Farinato A, Capitani E. A normative study on visual reaction times and two Stroop colour-word tests. Ital J Neurol Sci 19: 161-170 (1998).
23. Watson YI, Arfken CL, Birge SJ. Clock completion: an objective screening test for dementia. J Am Geriatr Soc 41: 1235-1240 (1993).
24. Amodio P, Wenin H, Del Piccolo F, Mapelli D, Montagnese S, Pellegrini A, et al. Variability of trail making test, symbol digit test and line trait test in normal people. A normative study taking into account age-dependent decline and sociobiological variables. Aging Clin Exp Res 14: 117-131 (2002).
25. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 256: 183-194 (2004).
26. Knopman DS, Boeve BF, Parisi JE, Dickson DW, Smith GE, Ivnik RJ. Antemortem diagnosis of frontotemporal lobar degeneration. Ann Neurol 57: 480-488 (2005).
27. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65: 1863-1872 (2005).
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34: 939-944 (1984).
29. Tian J, Bucks RS, Haworth J, Wilcock G. Neuropsychological prediction of conversion to dementia from questionable dementia: Statistically significant but not yet clinically useful. J Neurol Neurosurg Psychiatry 74: 433-438 (2003).
30. Portet F, Ousset PJ, Visser PJ, Frisoni GB, Nobili F, Scheltens P, et al. MCI working group of the European consortium on Alzheimer's disease (EADC). Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry 77: 714-718 (2006).
31. Bartenstein P, Asenbaum S, Catafau A, Halldin C, Pilowski L, Pupi A, et al. European association of nuclear medicine procedure guidelines for brain imaging using [18F]FDG. Eur J Nucl Med 29: BP43-BP48 (2002).
32. Oishi N, Udaka F, Kameyama M, Sawamoto N, Hashikawa K, Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 65: 1708-1715 (2005).
33. Villain N, Desgranges B, Viader F, de la Sayette V, Mézenge F, Landeau B, et al. Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's Disease. J Neurosci 28: 6174-6181 (2008).
34. Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ. Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol 42:129-138 (2007).
35. Chetelat G, Eustache F, Viader F, De La Sayette V, Pelerin A, Mezegne F, et al. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 11: 14-25 (2005).
36. Devanand DP, Folz M, Gorlyn M, Moeller JR, Stern Y. Questionable dementia: clinical course and predictors of outcome. J Am Geriatr Soc 45: 321-328 (1997).
37. Artero S, Tierney MC, Touchon J, Ritchie K. Prediction of transition from cognitive impairment to senile dementia: a prospective, longitudinal study. Acta Psychiatr Scand 107: 390-393 (2002).
38. Jagust W, Reed B, Mungas D, Ellis W, DeCarli C. What does fl uorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 69: 871-877 (2007).
39. Seo SW, Cho SS, Park A, Chin J, Na DL. subcortical vascular versus amnestic mild cognitive impairment: comparison of cerebral glucose metabolism. J Neuroimaging 19: 213-219 (2009).
40. De Toledo-Morrell L, Goncharova I, Dickerson B, Wilson RS, Bennett, DA. From healthy aging to early Alzheimer's disease: In vivo detection of entorhinal cortex atrophy. Ann NY Acad Sci 911: 240-253 (2000).
41. Killiany RJ, Hyman BT, Gomez-Isla T, Moss MB., Kikinis R, Jolesz F, et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology 58: 1188-1196 (2002).
42. De Toledo-Morrell L, Stoub TR, Bulgakova M, Wilson RS, Bennett DA, Leurgans S, et al. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging 25: 1197-1203 (2004).
43. Carmichael OT, Kuller LH, Lopez OL, Thompson PM, Dutton RA, Lu A, et al. Ventricular volume and dementia progression in the Cardiovascular Health Study. Neurobiol Aging 28: 389-397 (2007).
44. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 42: 85-94 (1997).
45. Mosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska L, et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry 63: 609-618 (2008).
46. Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 54: 343-351 (2003).
47. Magistretti PJ. Cellular bases of functional brain imaging: insights from neuron-glia metabolic coupling. Brain Res 886: 108-112 (2000).
48. De Santi S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, Roche A, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 22: 529-539 (2001).
49. Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, Convit A, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 64: 1860-1867 (2005).